PROFESSOR HÅKAN AXELSON is the group leader of the kidney cancer research group at the Department of Laboratory Medicine, Division of Translational Cancer Research and a member of the Lund University Cancer Center (LUCC).
WHAT IS THE FOCUS OF YOUR RESEARCH?
In our research we focus on kidney malignancies. In particular, we are interested in the relationship between normal kidney cells and molecular features of the different types of kidney cancer. We also study the cellular machinery responsible for adapting cells to low oxygen levels, as disturbances in this system initiates the most common type of kidney cancer.
WHAT IMPACT DO YOU HOPE YOUR RESEARCH WILL HAVE ON CANCER CARE/CANCER PATIENTS?
If the tumor is detected early, that is before the tumor has spread outside the kidney, surgery is often curative. Thus, early detection would be extremely valuable. We have shown that kidney cancer cells retain some of the unique features of normal kidney cells that can be exploited as biomarkers for both intervention and surveillance of the disease.
WHAT ARE THE POSSIBILITIES FOR COMMERCIALIZING YOUR RESEARCH?
In collaboration with Department of Urology we are currently investigating the clinical potential of the biomarkers mentioned above. Early diagnosis and disease monitoring would be very beneficial for the patients.
WHERE CAN I READ MORE ABOUT YOU AND YOUR RESEARCH?